[1] Zhao F, Xie X, Tan X, et al. The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis. Front Immunol, 2021, 12(1):691766. [2] Luo J, Liang X, Xin J, et al. Predicting the onset of hepatitis B virus-related acute-on-chronic liver failure. Clin Gastroenterol Hepatol, 2023, 21(3):681-693. [3] Tang X, Qi T, Li B, et al. Tri-typing of hepatitis B-related acute-on-chronic liver failure defined by the World Gastroenterology Organization. J Gastroenterol Hepatol, 2021, 36(1):208-216. [4] 黄涛,田琼林,张雪雪,等.慢加急性肝衰竭继发细菌感染病原菌及预后评估.中华医院感染学杂志,2022,32(6):861-865. [5] Wong F, Piano S, Singh V, et al. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. J Hepatol, 2021, 74(2):330-339. [6] Su H, Tong J, Liu X, et al. Characteristics and outcome of nosocomial bloodstream infection in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol, 2021, 33(1):83-88. [7] Gu Y, Chen L, Lian Y, et al. Serum HBV pregenomic RNA is correlated with Th1 / Th2 immunity in treatment-naïve chronic hepatitis B patients. J Med Virol, 2020, 92(3):317-328. [8] Wu ZB, Zheng YB, Wang K, et al. Plasma interleukin-6 level: A potential prognostic indicator of emergent HBV-associated ACLF. Can J Gastroenterol Hepatol, 2021, 11(2):5545181. [9] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2018,11(6):210-216. [10] 中华人民共和国卫生部.医院感染诊断标准.中华医学杂志,2001,81(5):315-320. [11] Yao N, He Y, Wu Y, et al. Prognostic value of plasma level of superoxide dismutase in HBV-related acute-on-chronic liver failure. BMC Gastroenterol, 2022, 22(1):312. [12] Xu W, Li Y, Wang L, et al. Efficacy and safety of combination treatment of double plasma molecular adsorption system and low volume plasma exchange for patients with hepatitis B virus related acute-on-chronic liver failure: a multicentre randomised controlled clinical trial. BMJ Open, 2021, 11(12):e047690. [13] 刘英辉,周东方,金国华,等.血清胃泌素与胃动素及炎症因子联合SIRS评分评估HBV-ACLF并发细菌感染的临床价值.中华医院感染学杂志,2021,31(11):1601-1606. [14] Hossain SMS, Mahtab MA, Das DC, et al. Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus related acute on chronic liver failure. J Family Med Prim Care,2021,10(7):2642-2645. [15] Weng WZ, Chen JF, Peng XH, et al. Risk factors for underlying comorbidities and complications in patients with hepatitis B virus-related acute-on-chronic liver failure. Epidemiol Infect, 2022, 50(1):e147. [16] Li C, Su HB, Liu XY, et al. Clinical characteristics and 28-d outcomes of bacterial infections in patients with hepatitis B virus-related acute-on-chronic liver failure. World J Clin Cases, 2020, 8(6):1042-1055. [17] 程晓燕,赵爱明,李海丹,等.慢加急性乙型肝炎肝衰竭患者医院感染病原菌分布及血清Th1/Th2型细胞因子水平变化.实用肝脏病杂志,2023,26(2):246-249. [18] Wang K, Zhang Z, Mo ZS, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure. Gut Microbes, 2021, 13(1):1-15. [19] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74(2):1014-1048. [20] Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med, 2021, 203(2):202-210. [21] Zhang DN, Liu Y, Li X, et al. Imbalance between soluble and membrane-bound CD100 regulates monocytes activity in hepatitis B virus-associated acute-on-chronic liver failure. Viral Immunol, 2021, 34(4):273-283. [22] Zhou C, Zhang N, He TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol, 2020, 26(30):4479-4488. |